{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:22:28Z","timestamp":1793830948105,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China, Regional Science Fund Project","award":["82160538"],"award-info":[{"award-number":["82160538"]}]},{"name":"Key Project of the Guizhou Provincial Basic Research Program","award":["ZD [2025] 023"],"award-info":[{"award-number":["ZD [2025] 023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04076-7","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:12:51Z","timestamp":1762780371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Han-Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Huan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"3","key":"4076_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"4076_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040646","volume":"17","author":"M Duchon","year":"2025","unstructured":"Duchon M, Naik R, Lecuru F, Ferron G, Cornou C, Madad Zadeh S, et al. Management of recurrence in ovarian cancer-the role of surgery and HIPEC with relevance to BRCA testing in a PARPi landscape. Cancers (Basel). 2025;17(4):646. https:\/\/doi.org\/10.3390\/cancers17040646.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4076_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J. Gynecological cancer intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419\u201323. https:\/\/doi.org\/10.1097\/IGC.0b013e3182070f17.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"4076_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, et al. NCCN guidelines\u00ae insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22(8):512\u20139. https:\/\/doi.org\/10.6004\/jnccn.2024.0052.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4076_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, P\u00f6lcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289\u201395. https:\/\/doi.org\/10.1097\/IGC.0b013e31820aaafd.","journal-title":"Int J Gynecol Cancer"},{"key":"4076_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejogrb.2018.06.036","volume":"228","author":"M Felsinger","year":"2018","unstructured":"Felsinger M, Minar L, Weinberger V, Rovny I, Zlamal F, Bienertova-Vasku J. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2018;228:154\u201360. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.06.036.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"4076_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(21)00006-1.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4076_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/BF00686037","volume":"34","author":"S Ohno","year":"1994","unstructured":"Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol. 1994;34(4):302\u20136. https:\/\/doi.org\/10.1007\/BF00686037.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4076_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, van Schagen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med"},{"issue":"10","key":"4076_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson SL, Lopez-Yurda M, Koole SN, van Schagen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023;24(10):1109\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(23)00396-0.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4076_CR11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","volume":"158","author":"JY Lee","year":"2023","unstructured":"Lee JY, Lee YJ, Son JH, Kim S, Choi MC, Suh DH, et al. Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy. JAMA Surg. 2023;158(11):1133\u201340. https:\/\/doi.org\/10.1001\/jamasurg.2023.3944.","journal-title":"JAMA Surg"},{"issue":"5","key":"4076_CR12","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135. https:\/\/doi.org\/10.1245\/s10434-014-4157-9.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4076_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127(3):502\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2012.09.020.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"4076_CR14","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","volume":"25","author":"JM Classe","year":"2024","unstructured":"Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024;25(12):1551\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00531-X.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4076_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.21037\/gs-23-293","volume":"12","author":"D Lee","year":"2023","unstructured":"Lee D, Lee J, Park H, Lee YJ, Lee JY, Nam EJ, et al. Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer. Gland Surg. 2023;12(12):1696\u2013704. https:\/\/doi.org\/10.21037\/gs-23-293.","journal-title":"Gland Surg"},{"issue":"23","key":"4076_CR16","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.21.00605","volume":"39","author":"O Zivanovic","year":"2021","unstructured":"Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O\u2019Cearbhaill RE. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for Platinum-Sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol. 2021;39(23):2594\u2013604. https:\/\/doi.org\/10.1200\/JCO.21.00605.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4076_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"issue":"7","key":"4076_CR18","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1200\/JCO.24.00686","volume":"43","author":"A Fagotti","year":"2025","unstructured":"Fagotti A, Costantini B, Fanfani F, Giannarelli D, De Iaco P, Chiantera V, et al. Hyperthermic intraperitoneal chemotherapy in Platinum-sensitive recurrent ovarian cancer: a randomized trial on survival evaluation (HORSE; MITO-18). J Clin Oncol. 2025;43(7):852\u201360. https:\/\/doi.org\/10.1200\/JCO.24.00686.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4076_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1245\/s10434-014-4049-z","volume":"22","author":"PA Cascales-Campos","year":"2015","unstructured":"Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, Gonz\u00e1lez-Gil A, L\u00f3pez V, et al. The role of hyperthermic intraperitoneal chemotherapy using Paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol. 2015;22(3):987\u201393. https:\/\/doi.org\/10.1245\/s10434-014-4049-z.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4076_CR20","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1245\/s10434-015-4991-4","volume":"23","author":"G Baiocchi","year":"2016","unstructured":"Baiocchi G, Ferreira FO, Mantoan H, da Costa AA, Faloppa CC, Kumagai LY, de Mello CA, Takahashi RM, Nakagawa WT, Aguiar S Jr. Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: A Single-center comparative analysis. Ann Surg Oncol. 2016;23(4):1294\u2013301. https:\/\/doi.org\/10.1245\/s10434-015-4991-4.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"4076_CR21","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/jog.15673","volume":"49","author":"D Yang","year":"2023","unstructured":"Yang D, Zhang Y, Gong P, Liu F, Gan Y, Bai W. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer. J Obstet Gynaecol Res. 2023;49(7):1795\u2013804. https:\/\/doi.org\/10.1111\/jog.15673.","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"4076_CR22","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","volume":"21","author":"JF Le Brun","year":"2014","unstructured":"Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol. 2014;21(11):3621\u20137. https:\/\/doi.org\/10.1245\/s10434-014-3693-7.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4076_CR23","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1245\/s10434-025-16979-6","volume":"32","author":"C Taliento","year":"2025","unstructured":"Taliento C, Restaino S, Arcieri M, Scutiero G, Greco P, Scambia G, et al. Cytoreductive surgery plus HIPEC in recurrent or newly diagnosed advanced epithelial ovarian cancer: a meta-analysis. Ann Surg Oncol. 2025;32(5):3648\u201359. https:\/\/doi.org\/10.1245\/s10434-025-16979-6.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4076_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7(5):100586. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100586.","journal-title":"ESMO Open"},{"issue":"2","key":"4076_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2014.602","volume":"112","author":"L Ansaloni","year":"2015","unstructured":"Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112(2):306\u201312. https:\/\/doi.org\/10.1038\/bjc.2014.602.","journal-title":"Br J Cancer"},{"issue":"8","key":"4076_CR26","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","volume":"7","author":"RM van Stein","year":"2021","unstructured":"van Stein RM, Aalbers AGJ, Sonke GS, van Driel WJ. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review. JAMA Oncol. 2021;7(8):1231\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0580.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4076_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ygyno.2021.01.039","volume":"161","author":"LM Chambers","year":"2021","unstructured":"Chambers LM, Yao M, Morton M, Gruner M, Chichura A, Horowitz M, et al. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol Oncol. 2021;161(2):389\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.039.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4076_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3322\/caac.21749","volume":"73","author":"JM Foster","year":"2023","unstructured":"Foster JM, Zhang C, Rehman S, Sharma P, Alexander HR. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin. 2023;73(1):49\u201371. https:\/\/doi.org\/10.3322\/caac.21749.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4076_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110424","volume":"51","author":"GB Guerra","year":"2025","unstructured":"Guerra GB, de Paiva Reis CM, de Menezes JSA, Val\u00e9rio-Alves AP, de Melo Sprogis R, Colares RA, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: a systematic review and meta-analysis of randomized control trials. Eur J Surg Oncol. 2025;51(11):110424. https:\/\/doi.org\/10.1016\/j.ejso.2025.110424.","journal-title":"Eur J Surg Oncol"},{"issue":"22","key":"4076_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12227012","volume":"12","author":"L Della Corte","year":"2023","unstructured":"Della Corte L, Conte C, Palumbo M, Guerra S, Colacurci D, Riemma G, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC): new approaches and controversies on the treatment of advanced epithelial ovarian cancer-systematic review and meta-analysis. J Clin Med. 2023;12(22):7012. https:\/\/doi.org\/10.3390\/jcm12227012.","journal-title":"J Clin Med"},{"issue":"3","key":"4076_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","volume":"167","author":"SI Kim","year":"2022","unstructured":"Kim SI, Kim JH, Lee S, Cho H, van Driel WJ, Sonke GS, et al. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis. Gynecol Oncol. 2022;167(3):547\u201356. https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.010.","journal-title":"Gynecol Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04076-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:12:18Z","timestamp":1762884738000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04076-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4076"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04076-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}